These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
500 related articles for article (PubMed ID: 29894577)
1. Characterisation of Cutibacterium acnes phylotypes in acne and in vivo exploratory evaluation of Myrtacine Pécastaings S; Roques C; Nocera T; Peraud C; Mengeaud V; Khammari A; Dréno B J Eur Acad Dermatol Venereol; 2018 Jun; 32 Suppl 2():15-23. PubMed ID: 29894577 [TBL] [Abstract][Full Text] [Related]
2. Change in Cutibacterium acnes phylotype abundance and improvement of clinical parameters using a new dermocosmetic product containing Myrtus communis and Celastrol enriched plant cell culture extracts in patients with acne vulgaris. Mias C; Thouvenin MD; Gravier E; Dalmon S; Bouyer K; Alvarez S; Mengeaud V; Ribet V; Bessou-Touya S; Duplan H J Eur Acad Dermatol Venereol; 2023 Mar; 37 Suppl 2():20-25. PubMed ID: 36729402 [TBL] [Abstract][Full Text] [Related]
3. Myrtus communis and Celastrol enriched plant cell culture extracts control together the pivotal role of Cutibacterium acnes and inflammatory pathways in acne. Mias C; Chansard N; Maitre M; Galliano MF; Garidou L; Mengeaud V; Bessou-Touya S; Duplan H J Eur Acad Dermatol Venereol; 2023 Mar; 37 Suppl 2():12-19. PubMed ID: 36729401 [TBL] [Abstract][Full Text] [Related]
4. [Phylotyping and Determining the Antimicrobial Susceptibility of Cutibacterium acnes Isolated from Patients with Acne Vulgaris]. Özel Kaya N; Usta İ; Demirçay ZÖ; Ülger Toprak N Mikrobiyol Bul; 2021 Oct; 55(4):465-479. PubMed ID: 34666649 [TBL] [Abstract][Full Text] [Related]
5. A Myrtus communis extract enriched in myrtucummulones and ursolic acid reduces resistance of Propionibacterium acnes biofilms to antibiotics used in acne vulgaris. Feuillolay C; Pecastaings S; Le Gac C; Fiorini-Puybaret C; Luc J; Joulia P; Roques C Phytomedicine; 2016 Mar; 23(3):307-15. PubMed ID: 26969384 [TBL] [Abstract][Full Text] [Related]
6. Decrease in Diversity of Propionibacterium acnes Phylotypes in Patients with Severe Acne on the Back. Dagnelie MA; Corvec S; Saint-Jean M; Bourdès V; Nguyen JM; Khammari A; Dréno B Acta Derm Venereol; 2018 Feb; 98(2):262-267. PubMed ID: 29136261 [TBL] [Abstract][Full Text] [Related]
7. A comparative study of Cutibacterium (Propionibacterium) acnes clones from acne patients and healthy controls. Lomholt HB; Scholz CFP; Brüggemann H; Tettelin H; Kilian M Anaerobe; 2017 Oct; 47():57-63. PubMed ID: 28434779 [TBL] [Abstract][Full Text] [Related]
8. Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: a brief look at the latest updates. Dréno B; Pécastaings S; Corvec S; Veraldi S; Khammari A; Roques C J Eur Acad Dermatol Venereol; 2018 Jun; 32 Suppl 2():5-14. PubMed ID: 29894579 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of topical 0.2% Myrtacine® and 4% vitamin PP for prevention and treatment of retinoid dermatitis in patients with mild to moderate acne. Veraldi S; Giovene GL; Guerriero C; Bettoli V G Ital Dermatol Venereol; 2012 Oct; 147(5):491-7. PubMed ID: 23007255 [TBL] [Abstract][Full Text] [Related]
10. Antimicrobial Susceptibility, Biotypes and Phylotypes of Clinical Cutibacterium (Formerly Propionibacterium) acnes Strains Isolated from Acne Patients: An Observational Study. Zhang N; Yuan R; Xin KZ; Lu Z; Ma Y Dermatol Ther (Heidelb); 2019 Dec; 9(4):735-746. PubMed ID: 31538294 [TBL] [Abstract][Full Text] [Related]
11. Analysis of distribution patterns of Propionibacterium acnes phylotypes and Peptostreptococcus species from acne lesions. Kwon HH; Yoon JY; Park SY; Suh DH Br J Dermatol; 2013 Nov; 169(5):1152-5. PubMed ID: 23795647 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of VB-1953 Topical Gel in Non-Responder Acne Patients with Clindamycin-Resistant Cutibacterium acnes. Batra R; Sadhasivam S; Saini S; Gupta S; Bisen RKS; Sinha M; Ghosh S; Jain S Drugs R D; 2020 Jun; 20(2):95-104. PubMed ID: 32222937 [TBL] [Abstract][Full Text] [Related]
13. Effect of zinc gluconate on propionibacterium acnes resistance to erythromycin in patients with inflammatory acne: in vitro and in vivo study. Dreno B; Foulc P; Reynaud A; Moyse D; Habert H; Richet H Eur J Dermatol; 2005; 15(3):152-5. PubMed ID: 15908296 [TBL] [Abstract][Full Text] [Related]
14. Biofilm of Cutibacterium acnes: a target of different active substances. Ruffier d'Epenoux L; Fayoux E; Veziers J; Dagnelie MA; Khammari A; Dréno B; Corvec S Int J Dermatol; 2024 Nov; 63(11):1541-1550. PubMed ID: 38760974 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological properties of Myrtacine® and its potential value in acne treatment. Fiorini-Puybaret C; Aries MF; Fabre B; Mamatas S; Luc J; Degouy A; Ambonati M; Mejean C; Poli F Planta Med; 2011 Sep; 77(14):1582-9. PubMed ID: 21452108 [TBL] [Abstract][Full Text] [Related]
17. Heterogeneity and antibiotic resistance in Propionibacterium acnes isolates and its therapeutic implications: blurring the lines between commensal and pathogenic phylotypes. Sadhasivam S; Sinha M; Saini S; Kaur SP; Gupta T; Sengupta S; Ghosh S; Sardana K Dermatol Ther; 2016 Nov; 29(6):451-454. PubMed ID: 27424878 [TBL] [Abstract][Full Text] [Related]
18. Antibiotic resistant Cutibacterium acnes among acne patients in Jordan: a cross sectional study. Alkhawaja E; Hammadi S; Abdelmalek M; Mahasneh N; Alkhawaja B; Abdelmalek SM BMC Dermatol; 2020 Nov; 20(1):17. PubMed ID: 33203374 [TBL] [Abstract][Full Text] [Related]
19. Taxonomy and phylogeny of Cutibacterium (formerly Propionibacterium) acnes in inflammatory skin diseases. Corvec S; Dagnelie MA; Khammari A; Dréno B Ann Dermatol Venereol; 2019 Jan; 146(1):26-30. PubMed ID: 30558958 [TBL] [Abstract][Full Text] [Related]
20. Antibiotic susceptibility of Propionibacterium acnes isolated from acne vulgaris in Korea. Song M; Seo SH; Ko HC; Oh CK; Kwon KS; Chang CL; Kim MB J Dermatol; 2011 Jul; 38(7):667-73. PubMed ID: 21352337 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]